user-generated· adoption
Wegovy pill market share exceeds 30% of oral GLP-1 prescriptions by M…
By March 31, 2027, the Wegovy pill will capture over 30% of all oral GLP-1 weight loss prescriptions in the US and UK combined, surpassing competitors like Zepbound (oral tirzepatide) and Mounjaro oral. This will be driven by brand recognition and strong efficacy data.
adoption · Prediction Market
- Implied probability (Yes)
- 67%
- Closes
- 2027-03-31
More adoption markets
- OpenAI Codex mobile usage exceeds desktop by Q1 2027 — 72% Yes
- OpenAI Codex mobile usage surpasses desktop within 6 months — 70% Yes
- PGA Tour Shop app downloads increase 25% YoY in 2026 — 68% Yes
- Bluesky's AT Protocol gains adoption by 3 major third-party apps by Q1 2027 — 55% Yes
- iOS 27 public release sees 20% adoption within first 6 weeks — 60% Yes
- Animal rights NGOs expand operations in Uganda by 2027 — 75% Yes
- Passive ETF inflows into SpaceX exceed $1.5 billion by October 2026 — 55% Yes
- Anthropic's enterprise AI share surpasses 30% by Q4 2026 — 75% Yes
Loading…